Corona Labs Inc.

Cresco Labs Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Alternative Medicine, Cannabis, Retail, Health, Tobacco, Natural Resources, Specialty, Webcast, EBITDA, FSE, Q2, CSE, Bank statement, Tax, Depreciation, Public expenditure, Boston, Eastern Time Zone, GAAP, Total, Cresco Labs, Growth, Corona Labs Inc., Drug, Bank, Fine chemical, Cryptocurrency, Security (finance), Q3

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the third quarter ended September 30, 2023.

Key Points: 
  • Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the third quarter ended September 30, 2023.
  • The financial information reported in this press release is based on unaudited management prepared financial statements for the quarter ended September 30, 2023.
  • The Company expects to file its unaudited condensed interim consolidated financial statements for the quarter ended September 30, 2023, on SEDAR+ on or about November 15, 2023.
  • Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers.

Thinkific Announces Suite of New Features for Thinkific Plus to Further Fuel the Growth of its Enterprise Platform for Customer Education

Retrieved on: 
Wednesday, December 6, 2023
Datadog, Plus, Multimedia, Compound annual growth rate, Growth, Corona Labs Inc., Market, TSX, News, Education, Video game, Tutoring, Online shopping, Hootsuite, Marketing

Plus provides enterprises with a robust, highly-secure and scalable learning management solution to educate, engage, and retain customers.

Key Points: 
  • Plus provides enterprises with a robust, highly-secure and scalable learning management solution to educate, engage, and retain customers.
  • The over 20 new tools launched on Thinkific Plus are focused on helping businesses leverage the power of customer education to fuel growth.
  • Through Thinkific Plus, we're providing a best-in-class platform, equipping businesses with tools to fuel growth, boost customer engagement, and enhance retention by harnessing the full potential of education."
  • Among a growing list of global corporations that use the platform, Hootsuite, Keap, DataDog, and Chargebee already successfully leverage Thinkific Plus to accelerate their customer education efforts.

Thinkific Joins Forces with Jon Youshaei to Launch 'Insider Accelerator' - a Premier Accelerator Program for Creators

Retrieved on: 
Tuesday, December 5, 2023
NPR, Negotiation, Human voice, Head, Student, Marketing, Partnership, Corona Labs Inc., Creator economy, Knowledge, TSX, Life, Business Insider, Music

The collaboration represents an extremely high profile Creator partnership for Thinkific and will see Jon and his team at Youshaei Studios produce a flagship accelerator program 'Insider Accelerator' designed to help more people become, and excel as, full-time Creators.

Key Points: 
  • The collaboration represents an extremely high profile Creator partnership for Thinkific and will see Jon and his team at Youshaei Studios produce a flagship accelerator program 'Insider Accelerator' designed to help more people become, and excel as, full-time Creators.
  • "This won't be just another course for Creators," Youshaei explained.
  • I couldn't be more excited to partner with Thinkific to bring this to life and help more Creators grow their audience — and their business."
  • During his three (3) years at Instagram, Jon helped empower even more Creators to grow and monetize their audiences.

Thinkific's A.I-Powered Creator Monetization Platform The Leap, Surpasses 6,500 Users in First Month

Retrieved on: 
Monday, November 6, 2023
AI, The Game Creators, The Leap, LEAP, Marketing, TSX, GM, Corona Labs Inc., Video game, Book

Since its release on October 4th, early adopters have created an impressive 5,000 digital products and counting.

Key Points: 
  • Since its release on October 4th, early adopters have created an impressive 5,000 digital products and counting.
  • This speed and ease of use is helping to drive the rapid uptick in users and positive sentiment around the platform.
  • The Leap has everything a Creator needs to launch their online business in a single end-to-end platform.
  • The link-in-bio storefront feature enables the Creator to accept payments and distribute and promote their digital products.

Consumer Automotive Finance, Inc. Announces Cancellation of 70,000,000 Common Shares

Retrieved on: 
Tuesday, October 31, 2023
NFL, Corona Labs Inc., Sport, Health, FINRA, Shell, OTC, Florida Gators, Athlete, OTCQB, Retirement, Nutrition, BCAA, Security (finance), Dietary supplement

MELBOURNE, Australia, Oct. 31, 2023 /PRNewswire/ -- Consumer Automotive Finance, Inc. (OTCPK: CAFI), a company that operates in the sports supplement, fitness equipment, and health and wellness industries, is pleased to announce it has reduced its issued and outstanding common shares of stock by seventy million (70,000,000) shares.

Key Points: 
  • MELBOURNE, Australia, Oct. 31, 2023 /PRNewswire/ -- Consumer Automotive Finance, Inc. ( OTCPK: CAFI ), a company that operates in the sports supplement, fitness equipment, and health and wellness industries, is pleased to announce it has reduced its issued and outstanding common shares of stock by seventy million (70,000,000) shares.
  • The Company is tightening up its share structure and will be working on its 15c2-11 along with uplisting to the OTCQB market tier.
  • The Company's new name, Fifty 1 Labs, Inc. is anticipated to go into effect within the next several weeks.
  • The Company recently announced it has launched its much-anticipated line of sports supplements and nutrition products under its "51" brand.

Consumer Automotive Finance, Inc. Announces the Expansion of its Corporate Office to 11,000 Sq Ft to Accommodate Growth from its Subsidiaries

Retrieved on: 
Tuesday, October 24, 2023
Labs, NFL, BCAA, Corona Labs Inc., Sport, Patent, Health, Whey protein, Quickness, Workforce, Form, Florida Gators, Athlete, Engineering, Growth, Marketing, Ticker, Retirement, Nutrition, DNA, 3D printing, Dietary supplement

MELBOURNE, Fla., Oct. 24, 2023 /PRNewswire/ -- Consumer Automotive Finance, Inc. (OTCPK: CAFI), a company that operates in the sports supplement, fitness equipment, and health and wellness industries, is pleased to announce it has expanded its corporate headquarters from 5,000 sq ft to 11,000 sq ft to accommodate the growth of its three subsidiaries, 51 Labs, The Quickness, and Astound NMN.  The added space will be utilized to expand its workforce with the addition of a sales team and for supplementary warehouse space.  The Company's subsidiary, 51 Labs, recently launched 10 all-new premium sports supplement products and is in the process of developing additional products.  The Company is also working on prototyping its patented product, The Quickness, which is a quick reflex training device originally designed to train linebackers speed, but will have other sports applications as well.

Key Points: 
  • The added space will be utilized to expand its workforce with the addition of a sales team and for supplementary warehouse space.
  • The Company's subsidiary, 51 Labs, recently launched 10 all-new premium sports supplement products and is in the process of developing additional products.
  • The Company recently announced it has launched its much-anticipated line of sports supplements and nutrition products under its "51" brand.
  • Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated.

Cresco Labs Unlocks $32 Million in Non-Dilutive Capital

Retrieved on: 
Thursday, October 19, 2023
Alternative Medicine, Cannabis, Retail, Health, Tobacco, Natural Resources, General Health, Sale, Health care, Corona Labs Inc., Public expenditure, CSE, Encanto, CL, Cresco Labs, FSE, Boston, Arizona Department, Arizona Department of Health Services, Cryptocurrency

In addition, the Company has closed on a conventional mortgage on its Ellenville, NY properties for a principal amount of up to $25.3 million with an interest rate of 8.43%.

Key Points: 
  • In addition, the Company has closed on a conventional mortgage on its Ellenville, NY properties for a principal amount of up to $25.3 million with an interest rate of 8.43%.
  • Our exit from Arizona aligns with our strategy of optimizing our portfolio by prioritizing assets with a greater path to scale,” said Charles Bachtell, CEO of Cresco Labs.
  • SSC Advisors acted as financial advisor to Cresco Labs.
  • Approximately $20 million was funded at close, with the remaining principal held to fund future capital expenditures.

Consumer Automotive Finance, Inc. Announces the Launch of its New Line of Sports Nutrition Products under its 51 Brand

Retrieved on: 
Wednesday, October 11, 2023
Foot, Patent, Ticker, Health, Sport, Corona Labs Inc., Retirement, Engineering, NFL, Florida Gators, DNA, Labs, Form, Quickness, BCAA, Growth, Marketing, Friends, University, Social media, Athlete, Nutrition, Creatine, 3D printing, Dietary supplement

The Company launched its new 51 website where all products can immediately be purchased.

Key Points: 
  • The Company launched its new 51 website where all products can immediately be purchased.
  • 51 is currently working on its Whey Protein line, which will be launching later this month.
  • The Company is working with universities to better understand athletes' nutritional needs, which will drive the development of future products.
  • With Brandon Spikes vast network of friends and fans on social media, we have high expectations for a successful launch."

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Retrieved on: 
Wednesday, September 20, 2023
Omicron, Animal, GeoVax, Face, SARS-CoV-2, Biotechnology, COVID-19, Georgia State University, Infection, Inflammation, Antibody, Protein, Protein structure, GEO, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Immune system, Cancer, Corona Labs Inc., Immunization, Death, MVA, Vaccine

ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen SARS-CoV-2 vaccine. The new unpublished data were presented during the Keystone Symposia on Molecular and Cellular Biology, Vaccinology During and After COVID-19, being held in Atlanta, Georgia on September 17-20, 2023.

Key Points: 
  • The new unpublished data were presented during the Keystone Symposia on Molecular and Cellular Biology, Vaccinology During and After COVID-19, being held in Atlanta, Georgia on September 17-20, 2023.
  • However, vaccine efficacy is disrupted by emerging variants that contribute to neutralizing antibody evasion, requiring updating and booster doses.
  • Together, these data indicate that immunization with the multi-antigen GEO-CM02 vaccine can protect against severe disease and death induced by SARS-CoV-2 infection and regardless of the variant.
  • The multi-antigen, MVA-vectored vaccine design is currently being evaluated by GeoVax in three Phase 2 clinical trials using a similar vaccine (GEO-CM04S1).”

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

Retrieved on: 
Thursday, September 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, GMP, Drug development, Depression, Anxiety, API, DSM-IV codes, FSE, Medicine, Active ingredient, Attention, Patient, Risk, OTC, Corona Labs Inc., NEO, Disease, Pharmaceutical industry, Fine chemical, Safety

Biomind’s groundbreaking achievement opens the door to new possibilities in drug development and medical research.

Key Points: 
  • Biomind’s groundbreaking achievement opens the door to new possibilities in drug development and medical research.
  • Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include:
    Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-DMT freebase.
  • This novel process ensures high purity and maintains the compound’s integrity, making it suitable for pharmaceutical applications.
  • Potential Therapeutic Applications: The availability of high-purity 5-MeO-DMT as an API paves the way for innovative research and development in various therapeutic areas.